At Google’s parent company, Alphabet, research and development spending rose to $31.56 billion in 2021. At Meta, that figure was $24.66 billion. Those figures amounted to 12.3 percent of revenue at Alphabet and 21 percent of sales at Meta, whereas S&P 500 companies spent 2.82 percent of revenue on research and development.
“Such investment from top-tier tech companies who are heavily vested in AI technology will naturally encourage and compel other companies, both tech and non-tech, such as pharmaceuticals,” Kyunghyun Cho, PhD, associate professor of computer and data science at New York University told the Journal.
This has already begun, with Google’s DeepMind offering AlphaFold for free, a program that predicts the way a protein folds. BioNTech also teamed up with a London-based AI start-up to create a program that predicts potential future COVID-19 variants with alarming accuracy.
These big tech investments into AI, paired with many of their pushes into the healthcare space, have the potential to produce the next generation of healthcare AI and IT.